ESTRO 2021 Abstract Book

S945

ESTRO 2021

Considering the growing incidence of both immune diseases and cancer, the interaction between RT and ARDs needs to be clearer.

PO-1137 A prospective study on Quality of life in patients treated with radiotherapy for early breast cancer F.C. Di Guglielmo 1,2 , L.A. Ursini 3 , M. Nuzzo 3 , C. Rosa 1,4 , M. Di Tommaso 3 , M. Trignani 3 , M. Borgia 3 , A. Allajbej 3 , F. Patani 3 , C. Di Carlo 3 , A. Porreca 5 , M. Di Nicola 6 , D. Genovesi 3,4 , L. Caravatta 3 1 SS. Annunziata Hospital, Department of Radiation Oncology , Chieti , Italy; 2 G. D'Annunzio University, Department of Neuroscience, Imaging and Clinical Sciences, Chieti , Italy; 3 SS. Annunziata Hospital , Department of Radiation Oncology , Chieti , Italy; 4 G. D'Annunzio University, Department of Neuroscience, Imaging and Clinical Sciences , Chieti , Italy; 5 G. D'Annunzio University, Department of Economics, Chieti, Italy; 6 G. D’Annunzio University of Chieti, Laboratory of Biostatistics, Department of Medical, Oral and Biotechnological Sciences, Chieti , Italy Purpose or Objective Advances in diagnosis and treatment of breast cancer (BC) have led to an increase in cancer survival, resulting in a greater remark on quality of life (QoL). Acute and late treatment-related side effects could influence QoL. This study aims to evaluate the impact of schedule of radiotherapy (RT), treatment related toxicities, Hormone therapy (HT) and age on QoL of early BC patients. Materials and Methods FACT-B 4.0 Italian version questionnaire was administered to a cohort of 95 patients at the start and end of RT and during follow-up controls. FACT-B 4.0 is a quick and well validated multi-dimensional self-report questionnaire with subscales measuring physical, social, emotional, and functional well-being and contains additional concerns in breast cancer. Acute or late toxicities were evaluated according to Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer. A comparison was made between fractionation (conventional or hypofractionation), HT and Age (< or > 65 years). Results All patients were early BC(IS:13.7%; I: 81.1% II:5.3%). The average age was 59.3 years (range 38-77) and the median follow-up was 16 months (6-22 months). Fifty-eight patients (61.1%) received hypofractionated regimen (42.5 Gy – 2.6 Gy/die) and 87,4 % of patients received adjuvant HT . The median trend of the QoL subscales was stable during all the five questionnaires. No difference was recorded between patients treated with Hypofractionated or Conventional RT. Radiotherapy did not affect FACT-B Total score (Functional Assessment of Cancer Therapy-General-Total), whereas HT negatively impacted on EWB (emotional wellbeing, p= 0.044), FWB (functional wellbeing, p= 0.009), and FACT-B-Total (p= 0.011) as shown in table 1. With respect to skin toxicity no differences were found for any of the variables. Regarding the age, although a significative worst G1 toxicity was assessed in older patients regarding acute skin toxicity (p-value < 0.001) and late sub-cutaneous toxicity (p-value= 0.013), our data did not show difference in QoL between two age groups (< 65 years vs ≥ 65 years), figure 2. Also concerning RT fractionation (p-value= 0.229) or HT (p-value= 0.057) no differences were detected.